UniQure Stock Jumps 15% On Study Update Of AMT-130 Gene Therapy For Huntington's Disease Treatment

Shares of uniQure N.V. (QURE) are gaining nearly 15% on Thursday morning after the gene therapy company announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease.

QURE is currently trading at $17.64, up $2.24 or 14.59%, on the Nasdaq. The stock has traded between $12.52 and $38.80 in the past 52-week period. The stock opened its trading at $17.07 after closing Wednesday's trading at $15.39.

Six of the 10 enrolled patients received AMT-130, and four patients received an imitation surgical procedure in this randomized, blinded clinical trial being conducted in the United States.

According to the results, treatment was generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up.

A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT